APLT vs. KALV, YMAB, VERV, AVTE, ATXS, ABUS, IGMS, TVTX, ALT, and LRMR Should you be buying Applied Therapeutics stock or one of its competitors? The main competitors of Applied Therapeutics include KalVista Pharmaceuticals (KALV), Y-mAbs Therapeutics (YMAB), Verve Therapeutics (VERV), Aerovate Therapeutics (AVTE), Astria Therapeutics (ATXS), Arbutus Biopharma (ABUS), IGM Biosciences (IGMS), Travere Therapeutics (TVTX), Altimmune (ALT), and Larimar Therapeutics (LRMR). These companies are all part of the "pharmaceutical preparations" industry.
Applied Therapeutics (NASDAQ:APLT ) and KalVista Pharmaceuticals (NASDAQ:KALV ) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, media sentiment, valuation, risk, earnings, community ranking, dividends, analyst recommendations and institutional ownership.
KalVista Pharmaceuticals' return on equity of -86.06% beat Applied Therapeutics' return on equity.
KalVista Pharmaceuticals received 258 more outperform votes than Applied Therapeutics when rated by MarketBeat users. Likewise, 73.93% of users gave KalVista Pharmaceuticals an outperform vote while only 56.35% of users gave Applied Therapeutics an outperform vote.
KalVista Pharmaceuticals has higher revenue and earnings than Applied Therapeutics. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Applied Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Applied Therapeutics had 2 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 3 mentions for Applied Therapeutics and 1 mentions for KalVista Pharmaceuticals. Applied Therapeutics' average media sentiment score of 1.32 beat KalVista Pharmaceuticals' score of 0.30 indicating that Applied Therapeutics is being referred to more favorably in the media.
Applied Therapeutics currently has a consensus target price of $11.00, indicating a potential upside of 162.53%. KalVista Pharmaceuticals has a consensus target price of $25.00, indicating a potential upside of 109.73%. Given Applied Therapeutics' higher probable upside, equities research analysts clearly believe Applied Therapeutics is more favorable than KalVista Pharmaceuticals.
98.3% of Applied Therapeutics shares are held by institutional investors. 8.6% of Applied Therapeutics shares are held by insiders. Comparatively, 12.3% of KalVista Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Applied Therapeutics has a beta of 1.91, meaning that its stock price is 91% more volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of 0.92, meaning that its stock price is 8% less volatile than the S&P 500.
Summary Applied Therapeutics beats KalVista Pharmaceuticals on 8 of the 15 factors compared between the two stocks.
This chart shows the number of new MarketBeat users adding APLT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart
Applied Therapeutics Competitors List
Related Companies and Tools
